BenevolentAI Investor Conference Presentation Deck
BEN-2293 - Atopic Dermatitis (AD)
• Atopic dermatitis is the most common chronic
inflammatory skin disease, characterized by intensely
itchy, red, and swollen skin(¹)
o Affects 10-20% of children and up to 3% of adults (²)
o Approximately 60-70% of all cases present with
mild-moderate disease severity(3)
●
o Prevalence is rising (3), with market value in 7MM
forecast to exceed $14 billion (2,4)
Skin inflammation and chronic pruritus associated
with atopic dermatitis negatively impact quality of life
and psychosocial well-being(¹)
Clear unmet need in mild to moderate patient
segment for treatment addressing itch and
inflammation, without side effects of steroids
BEN-2293: Topical best-in-class PanTrk inhibitor to
relieve inflammation and rapidly resolve itch in patients
with AD
BEN-2293 is a PanTrk inhibitor targeting TrkA, B and C
receptors. The Trk receptors were identified as part of an
effort to find mediators of both itch and inflammation
in AD. Using our Molecular Design expertise we were
able to design a PanTrk inhibitor, equipotent against the
3 receptors
BEN-2293 is expected to treat atopic dermatitis by:
inhibiting itch signaling and blocking nerve sensitization
(TrkA) in addition to inhibiting Th1 and Th2-mediated
dermal inflammation (TrkB, TrkC)
• BEN-2293 will target Mild, Moderate and Severe Atopic
Dermatitis patients, addressing unmet need in the
treatment of mild to moderate Atopic Dermatitis as a
steroid sparing alternative and in more severe patients
undergoing treatment with biologics (e.g. dupilumab)
that require add-on treatment
Sources: (1) Weidinger et al. Nat Rev Dis Primers 2018; (2) Global Data Report 2018: Atopic Dermatitis: Global Drug Forecast and
Market Analysis to 2027; (3) GlobalData Report 2018: Atopic Dermatitis: Epidemiology Forecast to 2027; (4) Evaluate Pharma
Benevolent 12View entire presentation